Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCL (Welchol)

Endocrine Practice

Volumn 19, Issue 2, 2013, Pages 275-283

  Mazze, Roger S ^a   Strock, Ellie S ^a   Monk, Arlene M ^b   Murphy, Matthew ^a   Xi, Min ^c   Bergenstal, Richard M ^b  

^a MAYO CLINIC   (United States)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c PARK NICOLLET INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESEVELAM; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; MINNESOTA; MONITORING, AMBULATORY; SULFONYLUREA COMPOUNDS;

EID: 84877136041     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12337.OR     Document Type: Article

References (19)

1. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-841.
2. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008:358;580-591.
4. Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabet Med. 2011; 28:856-864.
5. Hitman GA. Persistant lipid abnormalities in diabetes; are we approaching the treatment optimally? Diabet Med. 2011:28;1281.
6. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
7. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012; 55:432-442.
8. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2007;23:1673-1684.
9. Henry RR, Aroda VR, Mudaliar S, Garvey W, Chou HS, Jones MR. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14: 40-46.
10. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530.
11. Zieve FJ, Kalin MR, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74-83.
12. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Internal Med. 2007;168:1975-1983.
13. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Internal Med. 2008;168: 1531-1540.
14. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32:S237-S245.
15. Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008;10: 149-159.
16. Mazze R, Strock E, Morgan B, Wesley D, Cuddihy R, Bergenstal R. Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract. 2009;15;326-334.
17. World Medical Association. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul, October 2008.
18. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat. 1981;35:124-129.
19. Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care. 2012;35:1119-1125.